ICDs (implantable cardioverter defibrillators) look set to gain acceptance among physicians as the first-line treatment for heart patients
This article was originally published in Clinica
The implantable cardioverter defibrillator (ICD) is already replacing drug therapy as the primary treatment for the prevention of potentially fatal ventricular arrhythmias. Neena Brizmohun reports from a conference where cardiologists examined the reasons behind the increase in ICD use.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.